yallariyalla的个人主页 - 老虎社区

yallariyalla

yallariyalla

暂无个人介绍

IP属地：未知

32关注

1粉丝

0主题

0勋章

2021-07-24

$Electronic Arts(EA)$ I like EA

2021-07-11

Adobe

2021-07-06

Please like and comment

抱歉，原内容已删除

2021-07-14

$OncoSec Medical(ONCS)$when

2021-07-08

[强]

U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>

2021-07-22

$Palantir Technologies Inc.(PLTR)$waiting

2021-07-19

$Unity Software Inc.(U)$unity

2021-07-09

Good

抱歉，原内容已删除

2021-07-15

$Exxon Mobil(XOM)$ ?

2021-07-14

Apple

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586814184243615","uuid":"3586814184243615","gmtCreate":1623720498235,"gmtModify":1625552559724,"name":"yallariyalla","pinyin":"yallariyalla","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":32,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":174705209,"gmtCreate":1627135426601,"gmtModify":1631885229898,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EA\">$Electronic Arts(EA)$</a>&nbsp;I like EA","listText":"<a href=\"https://laohu8.com/S/EA\">$Electronic Arts(EA)$</a>&nbsp;I like EA","text":"$Electronic Arts(EA)$ I like EA","images":[{"img":"https://static.tigerbbs.com/420e9b4cb5092723ae53febbf9158492","width":"1440","height":"4179"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/174705209","isVote":1,"tweetType":1,"viewCount":1845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172297892,"gmtCreate":1626961711616,"gmtModify":1633769348478,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>waiting","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>waiting","text":"$Palantir Technologies Inc.(PLTR)$waiting","images":[{"img":"https://static.tigerbbs.com/ead2186460e668eeb639a55aa8bb44d1","width":"1440","height":"4063"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172297892","isVote":1,"tweetType":1,"viewCount":2726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":173694569,"gmtCreate":1626656463351,"gmtModify":1631883715242,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>unity","listText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>unity","text":"$Unity Software Inc.(U)$unity","images":[{"img":"https://static.tigerbbs.com/0167cc642b97fb3b3dd52095bff91bf9","width":"1440","height":"4179"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/173694569","isVote":1,"tweetType":1,"viewCount":3208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147629266,"gmtCreate":1626356710455,"gmtModify":1633927563774,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>good","text":"$Apple(AAPL)$good","images":[{"img":"https://static.tigerbbs.com/51f697651282563c2d998a1b81ef3a71","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147629266","isVote":1,"tweetType":1,"viewCount":2841,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147620897,"gmtCreate":1626356672219,"gmtModify":1631884931547,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XOM\">$Exxon Mobil(XOM)$</a>&nbsp;?&nbsp;","listText":"<a href=\"https://laohu8.com/S/XOM\">$Exxon Mobil(XOM)$</a>&nbsp;?&nbsp;","text":"$Exxon Mobil(XOM)$ ?","images":[{"img":"https://static.tigerbbs.com/3a344e15d7f70dda2f790c913983123c","width":"1440","height":"2790"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147620897","isVote":1,"tweetType":1,"viewCount":1796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144131954,"gmtCreate":1626271063878,"gmtModify":1631891063542,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>when","listText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>when","text":"$OncoSec Medical(ONCS)$when","images":[{"img":"https://static.tigerbbs.com/4c3be07da38c4b6dfe1919678f169f2c","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/144131954","isVote":1,"tweetType":1,"viewCount":3396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144109261,"gmtCreate":1626270450253,"gmtModify":1633928439691,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Still losing","listText":"Still losing","text":"Still losing","images":[{"img":"https://static.tigerbbs.com/77c8a5bc35cf68b6f677e3cfdbeb9ce3","width":"1440","height":"4001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144109261","isVote":1,"tweetType":1,"viewCount":3004,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144377632,"gmtCreate":1626270364126,"gmtModify":1633928440686,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[{"img":"https://static.tigerbbs.com/fec09762e45d5916d58fecc3dcaf202b","width":"1440","height":"4001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144377632","isVote":1,"tweetType":1,"viewCount":1765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":142174219,"gmtCreate":1626139186531,"gmtModify":1633929767355,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Share amd like","listText":"Share amd like","text":"Share amd like","images":[{"img":"https://static.tigerbbs.com/673d1a09418cf67dc9373e2a0a095113","width":"1440","height":"4117"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142174219","isVote":1,"tweetType":1,"viewCount":1824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":146408789,"gmtCreate":1626094745541,"gmtModify":1633930219814,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Buying soon","listText":"Buying soon","text":"Buying soon","images":[{"img":"https://static.tigerbbs.com/64a8c64d8dfc19e1454d2b48367ce05d","width":"1440","height":"4117"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146408789","isVote":1,"tweetType":1,"viewCount":1684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":146408157,"gmtCreate":1626094694679,"gmtModify":1631888958279,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>Still losing","listText":"<a href=\"https://laohu8.com/S/ZIM\">$ZIM Integrated Shipping Services Ltd.(ZIM)$</a>Still losing","text":"$ZIM Integrated Shipping Services Ltd.(ZIM)$Still losing","images":[{"img":"https://static.tigerbbs.com/3c9c3fd2f54a3f8e7a0ab442b147d5ab","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146408157","isVote":1,"tweetType":1,"viewCount":839,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148764916,"gmtCreate":1626019033335,"gmtModify":1633930880951,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Big fan of EA Fifa here","listText":"Big fan of EA Fifa here","text":"Big fan of EA Fifa here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148764916","repostId":"2150730700","repostType":2,"repost":{"id":"2150730700","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626017546,"share":"https://www.laohu8.com/m/news/2150730700?lang=zh_CN&edition=full","pubTime":"2021-07-11 23:32","market":"us","language":"en","title":"BRIEF-Electronic Arts Introduces EA Sports FIFA 22<blockquote>简介-艺电推出EA Sports FIFA 22</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2150730700","media":"Reuters","summary":"July 11 (Reuters) - Electronic Arts Inc   :   * INTRODUCED EA SPORTS FIFA 22   * ELECTRONIC ARTS - F","content":"<p><html><body>July 11 (Reuters) - Electronic Arts Inc   :</p><p><blockquote><html><body>路透7月11日-艺电公司：</body></html></blockquote></p><p>   * INTRODUCED EA SPORTS FIFA 22</p><p><blockquote>*介绍EA SPORTS FIFA 22</blockquote></p><p>   * ELECTRONIC ARTS - FIFA 22 TO BE AVAILABLE WORLDWIDE ON OCT 1 FOR VARIOUS DEVICES</p><p><blockquote>*Electronic Arts-FIFA 22将于10月1日在全球范围内适用于各种设备</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Electronic Arts Introduces EA Sports FIFA 22<blockquote>简介-艺电推出EA Sports FIFA 22</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Electronic Arts Introduces EA Sports FIFA 22<blockquote>简介-艺电推出EA Sports FIFA 22</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-07-11 23:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>July 11 (Reuters) - Electronic Arts Inc   :</p><p><blockquote><html><body>路透7月11日-艺电公司：</body></html></blockquote></p><p>   * INTRODUCED EA SPORTS FIFA 22</p><p><blockquote>*介绍EA SPORTS FIFA 22</blockquote></p><p>   * ELECTRONIC ARTS - FIFA 22 TO BE AVAILABLE WORLDWIDE ON OCT 1 FOR VARIOUS DEVICES</p><p><blockquote>*Electronic Arts-FIFA 22将于10月1日在全球范围内适用于各种设备</blockquote></p><p>Source text for Eikon:    Further company coverage:   </p><p><blockquote>Eikon的源文本：更多公司报道：</blockquote></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p><p><blockquote>（（Reuters.Briefs@thomsonreuters.com；））</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EA":"艺电"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150730700","content_text":"July 11 (Reuters) - Electronic Arts Inc   :   * INTRODUCED EA SPORTS FIFA 22   * ELECTRONIC ARTS - FIFA 22 TO BE AVAILABLE WORLDWIDE ON OCT 1 FOR VARIOUS DEVICESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"EA":1}},"isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":148768325,"gmtCreate":1626018632467,"gmtModify":1631888624971,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OIL\">$iPath Pure Beta Crude Oil ETN(OIL)$</a>oil","listText":"<a href=\"https://laohu8.com/S/OIL\">$iPath Pure Beta Crude Oil ETN(OIL)$</a>oil","text":"$iPath Pure Beta Crude Oil ETN(OIL)$oil","images":[{"img":"https://static.tigerbbs.com/9367e5a7efdff6c05f9aa98c12a89336","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/148768325","isVote":1,"tweetType":1,"viewCount":671,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148761445,"gmtCreate":1626018491387,"gmtModify":1631888035784,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Adobe","listText":"Adobe","text":"Adobe","images":[{"img":"https://static.tigerbbs.com/b7b838fca2e3d78e48922b815026f25a","width":"1440","height":"4117"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148761445","isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141915185,"gmtCreate":1625832806047,"gmtModify":1633936904480,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Declining&nbsp;[流泪]&nbsp;","listText":"Declining&nbsp;[流泪]&nbsp;","text":"Declining [流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141915185","repostId":"1181179663","repostType":4,"repost":{"id":"1181179663","kind":"news","pubTimestamp":1625822664,"share":"https://www.laohu8.com/m/news/1181179663?lang=zh_CN&edition=full","pubTime":"2021-07-09 17:24","market":"us","language":"en","title":"Oil prices firm as U.S. inventories decline<blockquote>美国库存下降油价坚挺</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1181179663","media":"Reuters","summary":"LONDON (Reuters) - Oil prices rose for a second day on Friday as data showed a draw in U.S. inventor","content":"<p>LONDON (Reuters) - Oil prices rose for a second day on Friday as data showed a draw in U.S. inventories, but were heading for a weekly loss amid uncertainty over global supplies after an OPEC+ impasse.</p><p><blockquote>伦敦（路透社）-由于数据显示美国库存减少，油价周五连续第二天上涨，但由于欧佩克+僵局后全球供应的不确定性，油价将出现每周下跌。</blockquote></p><p> Brent crude oil futures were up 60 cents, or 0.8%, at $74.72 a barrel by 0845 GMT. U.S. West Texas Intermediate futures were up 69 cents, or 1%, at $73.63.</p><p><blockquote>截至格林威治标准时间0845，布伦特原油期货上涨60美分，或0.8%，至每桶74.72美元。美国西德克萨斯中质原油期货上涨69美分，涨幅1%，报73.63美元。</blockquote></p><p> Prices on both sides of the Atlantic were on track for a weekly loss of nearly 2%, dragged down by the collapse of output talks between the Organization of the Petroleum Exporting Countries (OPEC) and allies including Russia, together known as OPEC+.</p><p><blockquote>受石油输出国组织（OPEC）与包括俄罗斯在内的盟友（统称为OPEC+）之间的产量谈判破裂拖累，大西洋两岸的价格有望每周下跌近2%。</blockquote></p><p> U.S. crude and gasoline stocks fell and gasoline demand reached its highest since 2019, the U.S. Energy Information Administration said on Thursday, signalling increasing strength in the economy.</p><p><blockquote>美国能源情报署周四表示，美国原油和汽油库存下降，汽油需求达到2019年以来的最高水平，表明经济实力增强。</blockquote></p><p> “A bullish EIA stock report helped the oil market rebound into the black,” said Stephen Brennock of oil broker PVM.</p><p><blockquote>石油经纪商PVM的Stephen Brennock表示：“看涨的EIA股票报告帮助石油市场反弹盈利。”</blockquote></p><p> “Clearly, U.S. oil markets are tight. However ... the only way to prevent further losses is for the threat of an OPEC+ price war to be contained,” he added.</p><p><blockquote>“显然，美国石油市场紧张。然而……防止进一步损失的唯一方法是遏制OPEC+价格战的威胁，”他补充道。</blockquote></p><p> Gains in oil prices were capped by worries that members of the OPEC+ group could be tempted to abandon output limits that they have followed during the COVID-19 pandemic, with talks breaking down because of an impasse between major producers Saudi Arabia and the United Arab Emirates.</p><p><blockquote>由于担心OPEC+集团成员国可能会试图放弃他们在COVID-19大流行期间遵循的产量限制，主要产油国沙特阿拉伯和阿拉伯联合酋长国之间的僵局导致谈判破裂，油价涨幅受到限制。</blockquote></p><p> The two Gulf OPEC allies are at odds over a proposed deal that would have brought more oil to the market.</p><p><blockquote>这两个海湾石油输出国组织盟友在一项将向市场带来更多石油的拟议协议上存在分歧。</blockquote></p><p> Russia was trying to mediate in an effort to strike a deal to raise output, OPEC+ sources said on Wednesday. The United States had high level conversations with officials in Saudi Arabia and the UAE, the White House said on Tuesday.</p><p><blockquote>OPEC+消息人士周三表示，俄罗斯正试图进行调解，以达成增产协议。白宫周二表示，美国与沙特阿拉伯和阿联酋的官员进行了高层对话。</blockquote></p><p> The global spread of the Delta coronavirus variant and worries it could stall a worldwide economic recovery also weighed on oil prices.</p><p><blockquote>德尔塔新冠病毒变异毒株的全球蔓延以及对其可能阻碍全球经济复苏的担忧也打压了油价。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oil prices firm as U.S. inventories decline<blockquote>美国库存下降油价坚挺</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOil prices firm as U.S. inventories decline<blockquote>美国库存下降油价坚挺</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-09 17:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>LONDON (Reuters) - Oil prices rose for a second day on Friday as data showed a draw in U.S. inventories, but were heading for a weekly loss amid uncertainty over global supplies after an OPEC+ impasse.</p><p><blockquote>伦敦（路透社）-由于数据显示美国库存减少，油价周五连续第二天上涨，但由于欧佩克+僵局后全球供应的不确定性，油价将出现每周下跌。</blockquote></p><p> Brent crude oil futures were up 60 cents, or 0.8%, at $74.72 a barrel by 0845 GMT. U.S. West Texas Intermediate futures were up 69 cents, or 1%, at $73.63.</p><p><blockquote>截至格林威治标准时间0845，布伦特原油期货上涨60美分，或0.8%，至每桶74.72美元。美国西德克萨斯中质原油期货上涨69美分，涨幅1%，报73.63美元。</blockquote></p><p> Prices on both sides of the Atlantic were on track for a weekly loss of nearly 2%, dragged down by the collapse of output talks between the Organization of the Petroleum Exporting Countries (OPEC) and allies including Russia, together known as OPEC+.</p><p><blockquote>受石油输出国组织（OPEC）与包括俄罗斯在内的盟友（统称为OPEC+）之间的产量谈判破裂拖累，大西洋两岸的价格有望每周下跌近2%。</blockquote></p><p> U.S. crude and gasoline stocks fell and gasoline demand reached its highest since 2019, the U.S. Energy Information Administration said on Thursday, signalling increasing strength in the economy.</p><p><blockquote>美国能源情报署周四表示，美国原油和汽油库存下降，汽油需求达到2019年以来的最高水平，表明经济实力增强。</blockquote></p><p> “A bullish EIA stock report helped the oil market rebound into the black,” said Stephen Brennock of oil broker PVM.</p><p><blockquote>石油经纪商PVM的Stephen Brennock表示：“看涨的EIA股票报告帮助石油市场反弹盈利。”</blockquote></p><p> “Clearly, U.S. oil markets are tight. However ... the only way to prevent further losses is for the threat of an OPEC+ price war to be contained,” he added.</p><p><blockquote>“显然，美国石油市场紧张。然而……防止进一步损失的唯一方法是遏制OPEC+价格战的威胁，”他补充道。</blockquote></p><p> Gains in oil prices were capped by worries that members of the OPEC+ group could be tempted to abandon output limits that they have followed during the COVID-19 pandemic, with talks breaking down because of an impasse between major producers Saudi Arabia and the United Arab Emirates.</p><p><blockquote>由于担心OPEC+集团成员国可能会试图放弃他们在COVID-19大流行期间遵循的产量限制，主要产油国沙特阿拉伯和阿拉伯联合酋长国之间的僵局导致谈判破裂，油价涨幅受到限制。</blockquote></p><p> The two Gulf OPEC allies are at odds over a proposed deal that would have brought more oil to the market.</p><p><blockquote>这两个海湾石油输出国组织盟友在一项将向市场带来更多石油的拟议协议上存在分歧。</blockquote></p><p> Russia was trying to mediate in an effort to strike a deal to raise output, OPEC+ sources said on Wednesday. The United States had high level conversations with officials in Saudi Arabia and the UAE, the White House said on Tuesday.</p><p><blockquote>OPEC+消息人士周三表示，俄罗斯正试图进行调解，以达成增产协议。白宫周二表示，美国与沙特阿拉伯和阿联酋的官员进行了高层对话。</blockquote></p><p> The global spread of the Delta coronavirus variant and worries it could stall a worldwide economic recovery also weighed on oil prices.</p><p><blockquote>德尔塔新冠病毒变异毒株的全球蔓延以及对其可能阻碍全球经济复苏的担忧也打压了油价。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/global-oil/update-3-oil-prices-firm-as-u-s-inventories-decline-idUSL2N2OL07F\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOM":"埃克森美孚"},"source_url":"https://www.reuters.com/article/global-oil/update-3-oil-prices-firm-as-u-s-inventories-decline-idUSL2N2OL07F","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181179663","content_text":"LONDON (Reuters) - Oil prices rose for a second day on Friday as data showed a draw in U.S. inventories, but were heading for a weekly loss amid uncertainty over global supplies after an OPEC+ impasse.\nBrent crude oil futures were up 60 cents, or 0.8%, at $74.72 a barrel by 0845 GMT. U.S. West Texas Intermediate futures were up 69 cents, or 1%, at $73.63.\nPrices on both sides of the Atlantic were on track for a weekly loss of nearly 2%, dragged down by the collapse of output talks between the Organization of the Petroleum Exporting Countries (OPEC) and allies including Russia, together known as OPEC+.\nU.S. crude and gasoline stocks fell and gasoline demand reached its highest since 2019, the U.S. Energy Information Administration said on Thursday, signalling increasing strength in the economy.\n“A bullish EIA stock report helped the oil market rebound into the black,” said Stephen Brennock of oil broker PVM.\n“Clearly, U.S. oil markets are tight. However ... the only way to prevent further losses is for the threat of an OPEC+ price war to be contained,” he added.\nGains in oil prices were capped by worries that members of the OPEC+ group could be tempted to abandon output limits that they have followed during the COVID-19 pandemic, with talks breaking down because of an impasse between major producers Saudi Arabia and the United Arab Emirates.\nThe two Gulf OPEC allies are at odds over a proposed deal that would have brought more oil to the market.\nRussia was trying to mediate in an effort to strike a deal to raise output, OPEC+ sources said on Wednesday. The United States had high level conversations with officials in Saudi Arabia and the UAE, the White House said on Tuesday.\nThe global spread of the Delta coronavirus variant and worries it could stall a worldwide economic recovery also weighed on oil prices.","news_type":1,"symbols_score_info":{"XOM":0.9,"CLmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":141913160,"gmtCreate":1625832457450,"gmtModify":1633936907995,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141913160","repostId":"2150371690","repostType":4,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141919784,"gmtCreate":1625832398548,"gmtModify":1633936908321,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"[美金]&nbsp;","listText":"[美金]&nbsp;","text":"[美金]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141919784","repostId":"1169516504","repostType":4,"isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":141910444,"gmtCreate":1625832318788,"gmtModify":1633936908895,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"[暗中观察]&nbsp;","listText":"[暗中观察]&nbsp;","text":"[暗中观察]","images":[{"img":"https://static.tigerbbs.com/90db90171e74dc72b4f5cbdd7a839043","width":"1440","height":"4117"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141910444","isVote":1,"tweetType":1,"viewCount":1106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":141937796,"gmtCreate":1625832275315,"gmtModify":1633936909465,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[OK]&nbsp;[强]&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>[OK]&nbsp;[强]&nbsp;","text":"$Apple(AAPL)$[OK] [强]","images":[{"img":"https://static.tigerbbs.com/3eebca906a8fbbec2a220c642980aa51","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141937796","isVote":1,"tweetType":1,"viewCount":1195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":149747237,"gmtCreate":1625751074829,"gmtModify":1633937731708,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149747237","repostId":"1184325113","repostType":4,"repost":{"id":"1184325113","kind":"news","pubTimestamp":1625750497,"share":"https://www.laohu8.com/m/news/1184325113?lang=zh_CN&edition=full","pubTime":"2021-07-08 21:21","market":"us","language":"en","title":"U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184325113","media":"Reuters","summary":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u","content":"<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>Biogen的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-08 21:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>Biogen的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184325113","content_text":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.\nShares of the company fell nearly 3% before the bell on Thursday.\nThe U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.\nAduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.\nSeveral members of the FDA’s advisory panel have resigned in protest over the approval.\nBiogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.\nThe new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.\nIt also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.\nThe new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.\nBiogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":174705209,"gmtCreate":1627135426601,"gmtModify":1631885229898,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EA\">$Electronic Arts(EA)$</a>&nbsp;I like EA","listText":"<a href=\"https://laohu8.com/S/EA\">$Electronic Arts(EA)$</a>&nbsp;I like EA","text":"$Electronic Arts(EA)$ I like EA","images":[{"img":"https://static.tigerbbs.com/420e9b4cb5092723ae53febbf9158492","width":"1440","height":"4179"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/174705209","isVote":1,"tweetType":1,"viewCount":1845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":148761445,"gmtCreate":1626018491387,"gmtModify":1631888035784,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Adobe","listText":"Adobe","text":"Adobe","images":[{"img":"https://static.tigerbbs.com/b7b838fca2e3d78e48922b815026f25a","width":"1440","height":"4117"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/148761445","isVote":1,"tweetType":1,"viewCount":693,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":154772415,"gmtCreate":1625549596637,"gmtModify":1633939733771,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/154772415","repostId":"2149033827","repostType":4,"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":144131954,"gmtCreate":1626271063878,"gmtModify":1631891063542,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>when","listText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>when","text":"$OncoSec Medical(ONCS)$when","images":[{"img":"https://static.tigerbbs.com/4c3be07da38c4b6dfe1919678f169f2c","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/144131954","isVote":1,"tweetType":1,"viewCount":3396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":149747237,"gmtCreate":1625751074829,"gmtModify":1633937731708,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149747237","repostId":"1184325113","repostType":4,"repost":{"id":"1184325113","kind":"news","pubTimestamp":1625750497,"share":"https://www.laohu8.com/m/news/1184325113?lang=zh_CN&edition=full","pubTime":"2021-07-08 21:21","market":"us","language":"en","title":"U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184325113","media":"Reuters","summary":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u","content":"<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>Biogen的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-08 21:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>Biogen的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184325113","content_text":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.\nShares of the company fell nearly 3% before the bell on Thursday.\nThe U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.\nAduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.\nSeveral members of the FDA’s advisory panel have resigned in protest over the approval.\nBiogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.\nThe new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.\nIt also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.\nThe new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.\nBiogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":892,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":172297892,"gmtCreate":1626961711616,"gmtModify":1633769348478,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>waiting","listText":"<a href=\"https://laohu8.com/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>waiting","text":"$Palantir Technologies Inc.(PLTR)$waiting","images":[{"img":"https://static.tigerbbs.com/ead2186460e668eeb639a55aa8bb44d1","width":"1440","height":"4063"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172297892","isVote":1,"tweetType":1,"viewCount":2726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":173694569,"gmtCreate":1626656463351,"gmtModify":1631883715242,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>unity","listText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>unity","text":"$Unity Software Inc.(U)$unity","images":[{"img":"https://static.tigerbbs.com/0167cc642b97fb3b3dd52095bff91bf9","width":"1440","height":"4179"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/173694569","isVote":1,"tweetType":1,"viewCount":3208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141913160,"gmtCreate":1625832457450,"gmtModify":1633936907995,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/141913160","repostId":"2150371690","repostType":4,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147620897,"gmtCreate":1626356672219,"gmtModify":1631884931547,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/XOM\">$Exxon Mobil(XOM)$</a>&nbsp;?&nbsp;","listText":"<a href=\"https://laohu8.com/S/XOM\">$Exxon Mobil(XOM)$</a>&nbsp;?&nbsp;","text":"$Exxon Mobil(XOM)$ ?","images":[{"img":"https://static.tigerbbs.com/3a344e15d7f70dda2f790c913983123c","width":"1440","height":"2790"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/147620897","isVote":1,"tweetType":1,"viewCount":1796,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":144377632,"gmtCreate":1626270364126,"gmtModify":1633928440686,"author":{"id":"3586814184243615","authorId":"3586814184243615","name":"yallariyalla","avatar":"https://static.tigerbbs.com/602bfd9ddb8884b3517f383042437991","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586814184243615","idStr":"3586814184243615"},"themes":[],"htmlText":"Apple","listText":"Apple","text":"Apple","images":[{"img":"https://static.tigerbbs.com/fec09762e45d5916d58fecc3dcaf202b","width":"1440","height":"4001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144377632","isVote":1,"tweetType":1,"viewCount":1765,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}